JPS58162530A - ガストリン性消化器癌抑制剤 - Google Patents
ガストリン性消化器癌抑制剤Info
- Publication number
- JPS58162530A JPS58162530A JP57043861A JP4386182A JPS58162530A JP S58162530 A JPS58162530 A JP S58162530A JP 57043861 A JP57043861 A JP 57043861A JP 4386182 A JP4386182 A JP 4386182A JP S58162530 A JPS58162530 A JP S58162530A
- Authority
- JP
- Japan
- Prior art keywords
- gastrin
- secretin
- cancer
- grandular
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010052343 Gastrins Proteins 0.000 title claims abstract description 40
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title claims abstract description 40
- 102100021022 Gastrin Human genes 0.000 title claims abstract 7
- 239000002246 antineoplastic agent Substances 0.000 title claims description 9
- 206010028980 Neoplasm Diseases 0.000 title abstract description 21
- 201000011510 cancer Diseases 0.000 title abstract description 11
- 210000004798 organs belonging to the digestive system Anatomy 0.000 title abstract description 3
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims abstract description 28
- 108010086019 Secretin Proteins 0.000 claims abstract description 27
- 102100037505 Secretin Human genes 0.000 claims abstract description 27
- 229960002101 secretin Drugs 0.000 claims abstract description 27
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 17
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 8
- 241000699660 Mus musculus Species 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 238000011580 nude mouse model Methods 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 229940088597 hormone Drugs 0.000 abstract description 3
- 239000005556 hormone Substances 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 210000000813 small intestine Anatomy 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 102400000921 Gastrin Human genes 0.000 description 33
- 230000000694 effects Effects 0.000 description 10
- 230000003042 antagnostic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003629 gastrointestinal hormone Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101001130458 Homo sapiens Ras-related protein Ral-B Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 102100031425 Ras-related protein Ral-B Human genes 0.000 description 1
- 108010012944 Tetragastrin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57043861A JPS58162530A (ja) | 1982-03-19 | 1982-03-19 | ガストリン性消化器癌抑制剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57043861A JPS58162530A (ja) | 1982-03-19 | 1982-03-19 | ガストリン性消化器癌抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58162530A true JPS58162530A (ja) | 1983-09-27 |
| JPH0235725B2 JPH0235725B2 (https=) | 1990-08-13 |
Family
ID=12675475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57043861A Granted JPS58162530A (ja) | 1982-03-19 | 1982-03-19 | ガストリン性消化器癌抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58162530A (https=) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5498315A (en) * | 1977-12-29 | 1979-08-03 | Hoechst Ag | Secretine preparation |
-
1982
- 1982-03-19 JP JP57043861A patent/JPS58162530A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5498315A (en) * | 1977-12-29 | 1979-08-03 | Hoechst Ag | Secretine preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0235725B2 (https=) | 1990-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors | |
| Dickens et al. | The carcinogenic action of aflatoxin after its subcutaneous injection in the rat | |
| US20200000776A1 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
| JPS5998015A (ja) | 免疫賦活剤 | |
| CN110833546A (zh) | 通佐溴胺在治疗胃癌中的用途 | |
| US3928580A (en) | Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins | |
| JPS62185028A (ja) | 後天性免疫不全症候群の処置用組成物 | |
| WO2025044424A1 (zh) | 一种基于免疫检查点阻断的抗肿瘤药物组合物及其应用 | |
| WO2023109704A1 (zh) | 一种抗体合成菌-纳米刺激剂杂合体及其抗肿瘤应用 | |
| DE69126038T2 (de) | Diagnose von krebs-metastasen durch das mts-1 gen | |
| Bennett et al. | Studies on the mechanism by which indomethacin increases the anticancer effect of methotrexate | |
| JPS58162530A (ja) | ガストリン性消化器癌抑制剤 | |
| Gadebusch et al. | Natural Host Resistance to Infection with Cryptococcus neoformans: V. The Influence of Cationic Tissue Proteins upon Phagocytosis and on Circulating Antibody Synthesis | |
| Tominaga et al. | Molecular signals in antigen presentation: I. Effects of interleukin 1 and 2 on radiation-treated antigen-presenting cells in vivo and in vitro | |
| CN111867598A (zh) | 肿瘤免疫赋活剂 | |
| Reiner et al. | Increased Growth of Tumor Isotransplants After Immunosuppression of the Recipient Mice by Methotrexate or 5-Fluoro-2′-Deoxyuridine | |
| CN115317493A (zh) | 一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用 | |
| Yamada et al. | Role of cellular and humoral factors in the destruction of nascent plasma cell tumors | |
| WO2020116989A1 (ko) | 생체내 세포 투입칩을 포함하는 항암용 조성물 | |
| CN112999211A (zh) | 神经酰胺分子在制备用于抑制食管鳞状细胞癌转移的药物中的应用 | |
| CN118105483B (zh) | Ox40激活抗体和抗血管生成剂在制备抗肿瘤药物中的应用 | |
| CN115869308A (zh) | 一种小分子化合物在制备抗结直肠癌药物中的应用 | |
| Debnath et al. | WCN26-3938 MINIMAL CHANGE DISEASE ASSOCIATED WITH RIBOCICLIB: A NOVEL RENAL COMPLICATION OF CDK4/6 INHIBITOR THERAPY | |
| CN121287903A (zh) | 一种car外泌体载药在肿瘤治疗中的应用 | |
| RU2166944C2 (ru) | Плазмозамещающий раствор с гемокоррегирующими и иммуномодулирующими свойствами |